tetano
Editor, Senior Moderator
Nature
. 2020 Jul 22.
doi: 10.1038/s41586-020-2571-7. Online ahead of print.
Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike
Lihong Liu[SUP] 1 [/SUP], Pengfei Wang[SUP] 1 [/SUP], Manoj S Nair[SUP] 1 [/SUP], Jian Yu[SUP] 1 [/SUP], Micah Rapp[SUP] 2 [/SUP], Qian Wang[SUP] 3 [/SUP], Yang Luo[SUP] 1 [/SUP], Jasper F-W Chan[SUP] 4 5 [/SUP], Vincent Sahi[SUP] 1 [/SUP], Amir Figueroa[SUP] 6 [/SUP], Xinzheng V Guo[SUP] 7 [/SUP], Gabriele Cerutti[SUP] 2 [/SUP], Jude Bimela[SUP] 2 [/SUP], Jason Gorman[SUP] 8 [/SUP], Tongqing Zhou[SUP] 8 [/SUP], Zhiwei Chen[SUP] 4 5 9 [/SUP], Kwok-Yung Yuen[SUP] 4 5 [/SUP], Peter D Kwong[SUP] 8 10 [/SUP], Joseph G Sodroski[SUP] 3 [/SUP], Michael T Yin[SUP] 11 [/SUP], Zizhang Sheng[SUP] 1 2 [/SUP], Yaoxing Huang[SUP] 12 [/SUP], Lawrence Shapiro[SUP] 13 14 15 [/SUP], David D Ho[SUP] 16 [/SUP]
Affiliations
Abstract
The SARS-CoV-2 pandemic rages on with devasting consequences on human lives and the global economy[SUP]1,2[/SUP]. The discovery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or prevent infection by this novel coronavirus. Here we report the isolation of 61 SARS-CoV-2-neutralizing monoclonal antibodies from 5 infected patients hospitalized with severe disease. Among these are 19 antibodies that potently neutralized the authentic SARS-CoV-2 in vitro, 9 of which exhibited exquisite potency, with 50% virus-inhibitory concentrations of 0.7 to 9 ng/mL. Epitope mapping showed this collection of 19 antibodies to be about equally divided between those directed to the receptor-binding domain (RBD) and those to the N-terminal domain (NTD), indicating that both of these regions at the top of the viral spike are immunogenic. In addition, two other powerful neutralizing antibodies recognized quaternary epitopes that overlap with the domains at the top of the spike. Cryo-electron microscopy reconstructions of one antibody targeting RBD, a second targeting NTD, and a third bridging two separate RBDs revealed recognition of the closed, "all RBD-down" conformation of the spike. Several of these monoclonal antibodies are promising candidates for clinical development as potential therapeutic and/or prophylactic agents against SARS-CoV-2.
. 2020 Jul 22.
doi: 10.1038/s41586-020-2571-7. Online ahead of print.
Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike
Lihong Liu[SUP] 1 [/SUP], Pengfei Wang[SUP] 1 [/SUP], Manoj S Nair[SUP] 1 [/SUP], Jian Yu[SUP] 1 [/SUP], Micah Rapp[SUP] 2 [/SUP], Qian Wang[SUP] 3 [/SUP], Yang Luo[SUP] 1 [/SUP], Jasper F-W Chan[SUP] 4 5 [/SUP], Vincent Sahi[SUP] 1 [/SUP], Amir Figueroa[SUP] 6 [/SUP], Xinzheng V Guo[SUP] 7 [/SUP], Gabriele Cerutti[SUP] 2 [/SUP], Jude Bimela[SUP] 2 [/SUP], Jason Gorman[SUP] 8 [/SUP], Tongqing Zhou[SUP] 8 [/SUP], Zhiwei Chen[SUP] 4 5 9 [/SUP], Kwok-Yung Yuen[SUP] 4 5 [/SUP], Peter D Kwong[SUP] 8 10 [/SUP], Joseph G Sodroski[SUP] 3 [/SUP], Michael T Yin[SUP] 11 [/SUP], Zizhang Sheng[SUP] 1 2 [/SUP], Yaoxing Huang[SUP] 12 [/SUP], Lawrence Shapiro[SUP] 13 14 15 [/SUP], David D Ho[SUP] 16 [/SUP]
Affiliations
- PMID: 32698192
- DOI: 10.1038/s41586-020-2571-7
Abstract
The SARS-CoV-2 pandemic rages on with devasting consequences on human lives and the global economy[SUP]1,2[/SUP]. The discovery and development of virus-neutralizing monoclonal antibodies could be one approach to treat or prevent infection by this novel coronavirus. Here we report the isolation of 61 SARS-CoV-2-neutralizing monoclonal antibodies from 5 infected patients hospitalized with severe disease. Among these are 19 antibodies that potently neutralized the authentic SARS-CoV-2 in vitro, 9 of which exhibited exquisite potency, with 50% virus-inhibitory concentrations of 0.7 to 9 ng/mL. Epitope mapping showed this collection of 19 antibodies to be about equally divided between those directed to the receptor-binding domain (RBD) and those to the N-terminal domain (NTD), indicating that both of these regions at the top of the viral spike are immunogenic. In addition, two other powerful neutralizing antibodies recognized quaternary epitopes that overlap with the domains at the top of the spike. Cryo-electron microscopy reconstructions of one antibody targeting RBD, a second targeting NTD, and a third bridging two separate RBDs revealed recognition of the closed, "all RBD-down" conformation of the spike. Several of these monoclonal antibodies are promising candidates for clinical development as potential therapeutic and/or prophylactic agents against SARS-CoV-2.